Stimuvax Phase 1/2 survival data support prior results

About this update from Cascade Copper Corp.

[{"type":"text","content":"\n\n\n\nBELLEVUE, WA, June 2 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY)\ntoday announced the presentation of two-year survival data from a Phase 1/2\nmulticenter study of Stimuvax(R) (BLP25 liposomal vaccine) in patients (n(equal sign)22)\nwith unresectable stage III non-small cell lung cancer. After a median\nfollow-up period of 26.7 months, the two-year overall survival rate was 64\npercent (95 percent confidence interval, 44-84 percent). The data were\npresented by Dr. N. R. Murray, British Columbia Cancer Agency, Fraser Valley\nCenter, Surrey, British Columbia, Canada, at the American Society of Clinical\nOncology Annual Meeting in Chicago on June 1, 2008.\n\n\n"The two-year overall survival data in the current study are similar to\nthe overall survival seen in a similar cohort of patients in Oncothyreon's\nprior Phase 2b trial of Stimuvax," said Robert L. Kirkman, M.D., President and\nCEO of Oncothyreon. "In that prior study, the two-year overall survival in\npatients with Stage IIIb loco-regional disease was 57 percent in those treated\nwith Stimuvax plus best supportive care compared with 33 percent in those who\nreceived best supportive care alone. We are very encouraged that the new data,\nobtained in the same patient population and with the same formulation of\nStimuvax being used in the ongoing Phase 3 trial, are supportive of our prior\nresults."\n\n\nThe Phase 1/2 trial was designed to evaluate the safety of Stimuvax\nfollowing a change in the manufacturer of the adjuvant component of the\nvaccine. No new safety concerns were identified in the study. The trial was\ncompleted by Merck KGaA of Darmstadt, Germany, which assumed responsibility\nfor the clinical development of Stimuvax in 2007.\n\n\nMerck KGaA currently is conducting a global Phase 3 trial of Stimuvax\nknown as START (Stimulating Targeted Antigenic Responses To NSCLC). START is a\nrandomized, double-blind, placebo-controlled study that will evaluate patients\nwith documented unresectable stage III NSCLC who have had a response or stable\ndisease after at least two cycles of platinum based chemo-radiotherapy. The\nPhase 3 trial is expected to enroll more than 1,300 patients in approximately\n30 countries. For more information on the START trial, or to find a\nparticipating center and eligibility criteria, log on to www.nsclcstu...

More updates from Cascade Copper Corp.